Drug Type Universal CAR-T |
Synonyms Alogeneic chimeric antigen receptor (CAR)-T cell therapy targeting mesothelin (MSLN) |
Target |
Action inhibitors |
Mechanism MSLN inhibitors(Mesothelin inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (United States) |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Pancreatic Cancer | Preclinical | United States | 07 May 2025 |





